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ABSTRACT  
Objective: Despite viral suppression and immune response on antiretroviral therapy (ART), 
people with HIV infection experience excess mortality compared to uninfected individuals. The 
Veterans Aging Cohort Study (VACS) Index incorporates clinical biomarkers of general health 
with age, CD4 count, and HIV-1 RNA to discriminate mortality risk in a variety of HIV positive 
populations. We asked whether additional biomarkers further enhance discrimination.  
 
Design and Methods: Using patients from VACS for development and from the Antiretroviral 
Therapy Cohort Collaboration (ART-CC) for validation, we obtained laboratory values from a 
randomly selected visit from 2000-2014, at least one year after ART initiation. Patients were 
followed for 5-year, all-cause mortality through September 2016. We fitted Cox models with 
established predictors and added new predictors based on model fit and Harrell’s c-statistic. We 
converted all variables to continuous functional forms and selected the best model (VACS Index 
2.0) for validation in ART-CC patients. We compared discrimination using c-statistics and 
Kaplan-Meier plots.  
 
Results: Among 28,390 VACS patients and 12,109 ART-CC patients, 7,293 and 722 died 
respectively. Nadir CD4, CD8, and CD4:CD8 ratio did not improve discrimination. Addition of 
albumin, white blood count (WBC), and body mass index (BMI), improved c-statistics in VACS 
from 0.776 to 0.805 and in ART-CC from 0.800 to 0.831. Results were robust in all 9 ART-CC 
cohorts, all lengths of follow-up and all subgroups .  
 
Conclusion VACS Index 2.0, adding albumin, WBC, and BMI to version 1.0 and using 
continuous variables, provides improved discrimination and is highly transportable to external 
settings. 
 
Key words: albumin, BMI, cohort study, comorbidity, mortality, prognostic index, validation 
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Introduction  
With antiretroviral treatment (ART), people with HIV infection (PWH) typically achieve 
and maintain viral suppression, leading to increases in CD4 count. However their health 
remains compromised compared with demographically similar individuals without HIV [1-4]. 
Therefore, the traditional HIV biomarkers (CD4 count and HIV-1 RNA level) are necessary but 
not sufficient metrics of health status for clinical management and research. The Veterans Aging 
Cohort Study (VACS) Index, a validated, generalizable risk index [5], employs routine clinical 
data to provide a summary metric of overall disease burden. Higher scores indicate increasing 
risk of all-cause mortality as well as hospitalization [6], medical intensive care admission [6], 
cardiovascular disease [7], fragility fractures [8] and cognitive compromise [9, 10]. The original 
VACS Index (version 1.0) includes age, CD4, HIV-1 RNA and general health biomarkers 
(hemoglobin, alanine and aspartate transaminases, platelets, creatinine and hepatitis C virus 
[HCV] sero-status). Adding these general health biomarkers to an index restricted to age, CD4 
and HIV-1 RNA substantially improved discrimination (c-statistic: 0.78 vs 0.72) [5]. The VACS 
Index is widely used in research for risk adjustment and as a clinical outcome. It is increasingly 
used in decision support tools available by website or app (https://vacs.med.yale.edu, 
https://www.mdcalc.com/veterans-aging-cohort-study-vacs-index), and in electronic health 
records.  
As currently constructed, VACS Index 1.0 has limitations. First, it categorizes predictors 
to simplify calculation and interpretation, limiting its ability to detect small changes, which 
commonly occur in longitudinal observation of an individual patient. Second, while discrimination 
(how well those who die are distinguished from those who do not die) is better than other risk 
indices in common use [11-14] addition of new predictors might further improve discrimination. 
While we have demonstrated that blood pressure, cholesterol and smoking do not improve 
discrimination of mortality in VACS Index 1.0 [15], our clinical team suggested other variables 
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that have been shown to be associated with poor outcomes. These include: nadir CD4, CD8, 
CD4:CD8 ratio [16, 17], albumin [18-21], white blood count (WBC) or absolute neutrophil count 
(ANC) [22, 23], and body mass index (BMI) [24, 25].  
We aimed to 1) develop an improved VACS Index (2.0) using data from United States 
(US) military veterans with HIV infection, 2) externally validate it using data from European and 
North American cohorts participating in the Antiretroviral Therapy Cohort Collaboration (ART-
CC), and 3) evaluate its generalizability among important subgroups.  
 
Methods  
Development of VACS Index 2.0 
We developed VACS Index 2.0 using patients from VACS, a cohort of all HIV-infected 
US military veterans in Veterans Health Administration (VA) care [26]. For this analysis, eligible 
patients were at least 18 years old, initiated ART between 1996 and 2014, and had a visit 
between 2000 and 2014. We excluded 2,782 individuals who had negative HCV RNA (at any 
time during the study period) after previously having detectable HCV RNA, because they may 
have received treatment for HCV infection or spontaneously cleared the virus. Few patients 
were treated prior to availability of direct acting antivirals (DAA) starting in 2014 and there is not 
yet long-term follow-up for those treated with DAAs. We obtained all laboratory values and BMI 
for a given individual for each visit date, at least one year after ART initiation. Values obtained 
prior to the visit date were allowed to carry forward for up to 180 days, resulting in complete 
information for 75% of visits. In sensitivity analysis, allowing values to carry forward for one 
year, 87% of visits had complete data. We randomly selected a visit date from among those with 
complete data to represent a typical patient in care. In addition to outpatient data, laboratory 
results obtained during hospitalization were included to provide a wider range of values. We 
only included one random day per hospitalization in the visit pool to avoid over-representation in 
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the sampled visit days. Patients were followed up to five years for, all-cause mortality until 
September 30, 2016. Ascertainment of deaths of VA patients is excellent [27, 28]. 
We first replicated the previously published VACS Index (1.0) by fitting a Cox model in 
the newly derived dataset using categorical predictors (age, CD4 count, HIV-1 RNA and 
laboratory measurements of hemoglobin, aspartate and alanine transaminases (AST, ALT), 
platelets, creatinine, and HCV status). Composite markers of liver and renal injury (FIB-4 and 
estimated glomerular filtration rate [eGFR] based on the CKDEPI equation) were calculated. 
FIB-4 (years of age×AST)/(platelets in 100/L×sqrt of ALT) is a validated indicator of liver fibrosis 
[29]. eGFR (141×min(SCr/κ, 1)α×max(SCr /κ, 1)-1.209×0.993Age×1.018 [if female]×1.159 [if black]; 
where κ=0.7 (females) or 0.9 (males); α=-0.329 (females) or -0.411 (males)); is a validated 
indicator of impaired renal function [30]. HCV infection status was based on detectable plasma 
HCV-RNA (85%) positive antibody test (10%) or documented diagnosis (5%). Once testing HCV 
positive, patients were assumed to remain positive (since we excluded treated patients). For 
comparison, we also modeled VACS Index 1.0 predictors as continuous vriables, as described 
below.   
We then evaluated candidate variables for addition to the VACS Index 1.0 model, one at 
a time and in combination using Akaike’s information criterion (AIC, lower is better) for model fit 
and Harrell’s c-statistic (range 0.5 to 1.0, higher is better) for discrimination. This was done 
using categorical variables with 10-level categories for each predictor with equal number of 
deaths in each category. We fitted a Cox model and plotted coefficients of categorized variables 
by median of each category. Categories were refined to adequately assess shape of the curve, 
maintaining at least 100 deaths per level. Then we determined an appropriate continuous 
functional form for each variable including quadratic, cubic, and natural log terms to account for 
U-shaped or J-shaped associations. Extreme values were replaced with the 1st or 99th 
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percentile to avoid undue influence; most variables were centered at the median. Splines were 
used if a suitable polynomial form was not found. Once a candidate final model was developed, 
we left out one variable at a time and compared model fit and discrimination to see if any 
predictor could be dropped without affecting model fit and discrimination. 
To create VACS Index scores, we used regression coefficients, estimated in this sample, 
for VACS Index 1.0 (original index, categorical variables) and VACS Index 2.0 (additional 
predictors, continuous variables). We applied regression equations to each patient using their 
individual lab values and the model coefficients to create linear predictors for each index, which 
were then scaled to create scores of approximately 0 to 100. To illustrate in a more clinically 
meaningful way, we calculated scores using a range of plausible values (between lowest and 
highest included in the model) for each predictor, while setting all others to the median.  The 
magnitude of the ranges of scores showed which predictors had the largest association. 
 
Validation of VACS Index 2.0 
We validated VACS Index 2.0 using data from ART-CC (described in detail elsewhere [31]), an 
international collaboration that combines data on PWH from European and North American 
cohorts. Eligible cohorts contributed data on the laboratory values of interest and reported at 
least 40 deaths in such patients. These were the AIDS Therapy Evaluation Project Netherlands 
(ATHENA), Austrian HIV Cohort Study (AHIVCOS), Italian Cohort of Antiretroviral-Naive 
Patients (ICONA), Aquitaine Cohort (France), Swiss HIV Cohort Study (SHCS), VACH (Spain), 
South Alberta Clinical Cohort (Canada), Tennessee Center for AIDS Research Cohort (US), and 
the University of Washington HIV Cohort (US). The nine included cohorts were randomly 
assigned a letter from A through I for anonymity. Patients and laboratory values were selected 
using the same approach as described above for VACS patients, but without any limitation of 
values obtained during hospitalization (as hospitalization dates were not available at the time of 
this analysis). The proportion of visit dates with complete information varied between 5% and 
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82% by cohort. Those with linkage to an electronic health record (EHR) had the highest 
proportion with complete data. In sensitivity analysis we compared discrimination between 
cohorts with at least 50% completeness to those with less than 50% completeness.  
Using VACS Index scores as predictors we compared performance in VACS and ART-
CC (overall and by cohort). We evaluated discrimination using c-statistics, hazard ratios per 5-
unit increase in VACS Index 2.0 score in Cox models, and Kaplan-Meier (KM) plots by decile of 
risk (customized for VACS and ART-CC so as to have equal number of deaths per decile).  We 
evaluated discrimination at varying lengths of follow-up (30 days, 90 days, 6 months, 1, 2, 3, 4 
and 5 years) using fixed weights from 5-year outcome models developed in VACS.  
 
Performance across subgroups  
Finally, development and validation datasets were combined to evaluate index 
performance in important patient subgroups [women; those with HIV-1 RNA<500 copies/mL; 
HCV co-infected patients; and low-risk patients defined according to conventional HIV indicators 
(age <50 years, CD4 ≥200 cells/mm3 and HIV-1 RNA ≤500 copies/mL)]. Those not meeting 
criteria for low-risk were categorized as high-risk. We calculated c-statistics and calculated 
mortality rates in patients defined as low-risk and high-risk as a function of VACS Index 2.0 
score.  
 
We used SAS version 9.4 (SAS Institute, Cary, North Carolina, USA) for all analyses, 
except that calculation of Harrell’s c-statistic used Stata version 14 (Stata Corp., College Station, 
Texas, USA). Institutional review boards from each cohort approved analysis of routinely collected 
data. 
 
Results  
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Half the randomly selected visit dates were in 2010 and later (Table 1). Among 28,390 
VACS patients there were 7,293 deaths (7.2 per 100 person-years (PY)); 39% occurred in the 
first year of follow-up. Median time on ART as of the random visit date was 4.2 years; 
subsequent median follow-up was 4.1 years. Among 12,109 ART-CC patients there were 722 
deaths (2.0 per 100 PY, ranging 1.2 to 4.5 by cohort); 44% occurred in the first year. Median 
time on ART was 4.2 years, median follow-up was 3.2 years. Compared to ART-CC, VACS 
patients were older (median 53 vs 43 years), more likely to be male (98% vs 74%) and more 
likely to have initiated ART before 1999 (Table 1). VACS patients were less likely than ART-CC 
patients to be virally suppressed (76% vs 88%) and be defined as low-risk (24% vs 60%). 
In VACS (development) data, model fit and discrimination improved with addition of 
CD4:CD8 ratio, BMI, albumin and WBC, individually and in combination, compared to VACS 
Index 1.0 (Appendix Figure 1). However, removal of CD4:CD8 ratio from the candidate final 
model did not decrease performance so it was dropped. Prediction was not improved with 
addition of nadir CD4 or CD8 count. WBC and ANC were highly correlated (r = 0.87) and 
performed equally well, but WBC was more widely available. The final VACS Index 2.0, using all 
continuous variables, included all original variables (age, CD4 count, HIV-1 RNA, hemoglobin, 
FIB-4, eGFR, and HCV status) plus albumin, WBC, and BMI. Suitable polynomial forms were 
found for all variables except eGFR which was modeled using splines (Appendix Table 1).  
Extending last value carried forward time to one year provided <3% additional visit dates or 
deaths, and all estimates were similar to those obtained using 180 days in the main analysis. 
 When we calculated scores using a plausible range of values: age and albumin had the 
greatest influence. To illustrate, age 30 corresponds to 32 points and age 75 corresponds to 59 
points, for a range of 27 points. An albumin value of 2.0 g/dl corresponds to 65 points and 5.0 
g/dl corresponds to 39 points, for a range of 26 points (Appendix Table 2). CD4 count (10-900 
cells/ul, 23 points), HIV-1 RNA (1.3-5.0 log10 copies/mL, 18 points), FIB4 (0.5-7.5, 20 points), 
BMI (15-35 kg/m2, 20 points), hemoglobin (9-16 g/dl, 16 points), and eGFR (0-180 ml/min, 16 
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points) were also quite influential on total score. In contrast HCV (yes or no, 6 points) was the 
least influential, as in VACS Index 1.0.  
VACS Index 2.0 scores were 10 points higher in VACS (median 51, interquartile range 
39-66) than in ART-CC (41, 33-52), with little variation by cohort except for Cohort C (35, 27-
46). Scores were approximately normally distributed, but slightly right skewed (means: 54 in 
VACS, 44 in ART-CC). With these risk scores as the sole predictor in Cox models, mortality 
hazard ratios associated with a 5-point increment of score were 1.31 (95% confidence interval 
[CI], 1.30-1.31) in VACS and 1.37 (1.35-1.39) in ART-CC with little variation by cohort (range 
1.34 to 1.41) (Appendix Table 3).  In VACS (development) data, the c-statistic increased from 
0.779 (95% CI 0.774, 0.784) for VACS Index 1.0 to 0.786 (0.781, 0.791) using continuous 
predictor variables limited to VACS Index 1.0 predictors. The c-statistic further increased to 
0.805 (0.800, 0.810) after addition of albumin, WBC, and BMI (VACS Index 2.0). Corresponding 
c-statistics in the ART-CC (validation) data were 0.800 (0.782, 0.818) for VACS Index 1.0; 0.808 
(0.790, 0.825) for continuous VACS 1.0 predictors and 0.831 (0.814, 0.847) for VACS Index 2.0.  
C-statistics improved in all 9 ART-CC cohorts (Figure 1a). In cohorts with at least 50% 
completeness in the visit pool and in those with less than 50% completeness, the c-statistic was 
greater with VACS Index 2.0, with no separation in the confidence intervals comparing 
completeness. At all follow-up intervals VACS Index 2.0 had greater discrimination than VACS 
Index 1.0 (Figure 1b and 1c). As expected, c-statistics were greater for shorter follow-up times. 
Additionally, improvement from VACS Index 1.0 to 2.0 was greatest for shorter follow-up times. 
Kaplan-Meier plots by decile of risk (Figure 2 and Appendix Table 4) for VACS showed 
better separation with VACS Index 2.0 compared to 1.0, especially in earlier years of follow-up. 
With VACS Index 1.0 deciles 6 and 7 overlapped until 1 year.  With VACS Index 2.0 all deciles 
were distinct at about 6 months of follow-up. The range of 5-year survival for extreme deciles 
expanded from 13-92% with VACS Index 1.0 to 8-93% with VACS Index 2.0. More than 100 
people were still under follow-up at five years for VACS Index 2.0 deciles 1-8. In the 9th decile 
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729/888 people had died by 5 years and 95 remained. In the 10th decile 399/811 people had 
died by 6 months, and 730 by 5 years, with 41 remaining. 
In ART-CC, with only one-tenth as many deaths, the curves were less distinct, but still 
showed improvement with VACS Index 2.0 (Figure 2 and Appendix Table 4). The range of 5-
year survival expanded from 35-97% with VACS Index 1.0 to 25-98% with VACS Index 2.0. 
Similar patterns were seen with 1-year survival. . More than 100 people were still under follow-
up at five years in deciles 1-5. In the 9th decile 71/151 people had died by 5 years and 15 
remained. In the 10th decile 44/114 people had died by 6 months, and 73 by 5 years, with 15 
remaining. In both VACS and ART-CC median survival was less than a year for those in the 
highest VACS Index 2.0 decile. Based on the above findings we combined VACS and ART-CC 
data to look at subgroups.  
In combined data, we found higher c-statistics for VACS Index 2.0 than VACS Index 1.0 
for all subgroups (Figure 3): age <50(0.85, 0.83), age 50+ (0.79, 0.75), men (0.82, 0.79), 
women (0.84, 0.80), suppressed virus (0.82, 0.78), unsuppressed virus (0.77, 0.75), HIV mono-
infected (0.82, 0.79) and HCV co-infected (0.75, 0.72) and patients defined as low-risk (0.79, 
0.73) and high-risk (0.79, 0.76). 
Mortality rates in both low-risk and high-risk patients had strong and similar associations 
with VACS Index 2.0 score (Figure 4). 
  
Discussion 
Compared with VACS Index 1.0, VACS Index 2.0 had better discrimination in development 
(VACS) and external validation (ART-CC) data. This was achieved by study design; treating all 
predictors as continuous; and adding albumin, WBC, and BMI. Improved discrimination was 
evident across a variety of clinically defined subgroups, varying length of follow-up and across 
ART-CC cohorts. Improved discrimination was evident beyond c-statistics. Compared to VACS 
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Index 1.0, Kaplan-Meier plots comparing deciles of VACS Index 2.0 showed better separation of 
mortality risk during the first 6-12 months of follow-up that persisted across the 5-year follow up. 
In both low-risk and high-risk patients there was a strong and consistent gradient of higher 
mortality with increasing score. Importantly, improved discrimination of VACS Index 2.0 is 
generalizable across clinically important subgroups and among individual cohorts and 
transportable to other settings [32].  
Thus, VACS Index 2.0 can be used as a measure of disease burden for risk adjustment 
and/or as an outcome for clinical research. With automated calculation and risk interpretation by 
way of smartphone apps, online calculators, or decision support modules in EHRs, it can also 
be incorporated in medical decision making.  
Generalizability of VACS Index 2.0 was likely enhanced by the design of the current 
study. Because we started follow-up from a randomly selected date, the index was designed 
around a typical patient in care, rather than optimizing for patients at some fixed point after 
initiating ART. We did not restrict to patients who were ART naïve at study entry. Including 
laboratory values obtained during hospitalization increased the range of severity of illness 
represented in the model development dataset. 
Importantly, VACS Index 2.0 predictors are continuous, offering important advantages 
over the thresholds in VACS Index 1.0. For example, on the day a patient turns 50 the VACS 
Index 1.0 score increases by 12 points, translating to roughly 40% increased risk of mortality. 
While this increased risk is accurate in aggregate for those aged 50-64 years, it is not realistic 
for an individual to have such an abrupt change in risk. VACS Index 2.0 models this change in 
risk smoothly across ages. Thresholds used in VACS Index 1.0 limited investigator’s ability to 
use the index as an outcome to detect change from baseline to end of observation. With the 
higher resolution provided by continuous variables more subtle changes in risk can be detected, 
enhancing suitability for longitudinal patient monitoring. 
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Addition of albumin, WBC, and BMI both enhanced discrimination of the VACS Index as 
a metric of mortality risk, and provided interesting insights. After age, albumin has become the 
single most important marker of general health in the model. Low serum albumin levels may be 
associated with multiple conditions that are related to HIV (e.g. poor nutritional status, 
inflammation, nephropathy, and liver disease). We suspect that albumin is particularly important 
as an added indication of liver disease, which is increasingly common among those aging with 
HIV. In VACS Index 1.0 liver injury was only ascertained with FIB-4 and an indicator for HCV 
infection. Albumin measures liver synthetic function thus enhancing detection of significant liver 
injury. We chose not to include hospitalization as a predictor in the index for several reasons. 
We want to use the VACS Index to predict future hospitalization. Second, hospitalization can be 
considered a downstream effect in the causal pathway between VACS Index components and 
subsequent death. As such, inclusion would obfuscate associations with the validated 
predictors. Finally, varying causes of hospitalization would have differential associations with 
mortality risk.   
VACS Index 2.0 is a stronger predictor than the original. Despite having similar range of 
scores, the hazard ratio for 5-year, all-cause mortality increased from 1.221 (1.216-1.227) per 5 
points with VACS Index 1.0, to 1.307 (1.300-1.314) per 5 points with VACS Index 2.0. VACS 
Index 2.0 is better able to identify very high-risk patients with as little as 6 months of follow-up, a 
time frame of concern to both clinicians and patients. In the 10th decile on the Kaplan-Meier 
plots, estimated 6-month survival in VACS patients decreased from 61% with VACS Index 1.0 to 
51% with VACS Index 2.0. In ART-CC this change was 74% to 59%. 
Interestingly, VACS Index 2.0 had higher discrimination in validation (ART-CC) than in 
development (VACS). This was also observed in our original validation of VACS Index 1.0 in 
ART-CC [5]. There are several possible explanations for this. First, the follow up time in ART-
CC is shorter and, all else being equal, more proximal deaths are easier to predict than more 
distant deaths. Second, ART-CC subjects are younger and discrimination is slightly better 
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among those under 50 years of age. Finally, the index is not designed to detect risk of unnatural 
deaths, such as suicide, accident, or overdose. These deaths are more common in the military 
veteran population [33, 34]. 
 A common problem in prognostic modelling is that some subgroups may be 
underrepresented in a development sample, such as women in VACS. Therefore, it is important 
to demonstrate that the index can discriminate well within these underrepresented but clinically 
important subgroups. We found superior discrimination with VACS Index 2.0 in all subgroups 
(including women) and among each of the nine participating cohorts in ART-CC. These 
observations offer strong evidence that improved discrimination of VACS Index 2.0 will 
generalize to new populations. It also suggests that the strong associations previously 
demonstrated with VACS Index 1.0 and biomarkers of inflammation [16, 35-37], hospitalization 
and medical intensive care unit admission [38], myocardial infarction [7], neurocognitive 
performance [9, 10], and fragility fractures [8, 39] will hold for VACS Index 2.0. 
Improvement in discrimination was particularly large in cohort F, increasing from 0.790 
(95% CI 0.744, 0.835) with VACS Index 1.0 to 0.873 (0.841, 0.906) with VACS Index 2.0. This 
cohort had one of the highest proportions of death in the first year of follow-up and did not 
supply race data, possibly resulting in under-estimation of eGFR. With addition of albumin to 
VACS Index 2.0, eGFR became a weaker predictor so the potential impact of this 
misclassification would have decreased. Furthermore only 5% of Cohort F patient visits had 
complete data, so only a small fraction of the entire cohort is included. The proportion with 
hemoglobin <12 is 23%, highest of all cohorts.  Albumin, the least available lab, was only 
present for 12% of patients. Per the cohort principal investigator, “selecting people with both 
hemoglobin and albumin present will give a selection of people who are sicker than the rest of 
the cohort.” This assessment is supported by the finding that 40% of the deaths occurred in the 
first 6 months, 10% higher (absolute) than any other cohort, consistent with differentially sick 
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patients. As noted in Figure 1c, the increase from VACS Index 1.0 to 2.0 was greater for shorter 
follow-up times. 
 
The original VACS Index has been increasingly used in a variety of research, public 
health, and clinical settings. As of August 1, 2018 the VACS Index Risk Calculator (link above) 
has been accessed >80,000 times since March of 2013 and most of these represent repeated 
use. The VACS Index has been used as a risk adjuster in observational studies [25, 40]. It is 
also useful in randomized clinical trials. Two NIH funded, alcohol intervention trials are 
underway which include the VACS Index as an outcome. The AIDS Clinical Trials Group has 
begun to use the VACS Index in randomized trials [41]. Independent groups are now using the 
VACS Index as a measure of frailty or severity of illness [10, 36, 37, 42-50]. In addition, the 
VACS Index is being used in public health surveillance. The Public Health-Seattle & King 
County, HIV/STD Program and the Washington State Department of Health use the VACS 
Index to monitor risk of mortality and burden of disease among PWH. Several health systems 
have incorporated the index as a patient management tool within their EHR. These include: 
Fenway Healthcare System in Boston; San Francisco General Hospital HIV Clinic and 
University of California, San Diego Owen Clinics. In Italy, the VACS Index is calculated on every 
patient seen at the University of Modena Metabolic Clinic. Providers use these data to target 
care to the sickest patients and in overall patient management. The modifications in VACS 
Index 2.0 will enhance its utility for all these applications.  
An important limitation of VACS Index 2.0 is that we have not incorporated the 
prognostic implications of HCV cure. For this analysis, we excluded those who were treated for 
HCV from the development sample. In the validation sample most of the follow-up is before 
widespread availability of DAAs. But treatment of HCV may still have influenced our findings. In 
future work we hope to address this limitation once adequate mortality data are available among 
PWH successfully treated for HCV co-infection. Another limitation is that we could only consider 
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nadir CD4 as observed within the VA EHR and we cannot be sure it is truly the lowest CD4 cell 
count prior to ART initiation. However, this is likely more a limitation of the metric since lack of 
prior history can be a common problem when patients present to a new clinic for care. Missing 
data may also be a concern. We only randomly selected visit dates when patients had complete 
data within the prior 180 days. Nonetheless we found consistent results across all cohorts 
regardless of the proportion of visits with complete data. Finally, we have yet to conduct 
analyses determining the calibration of VACS Index 2.0. As with the original index, we plan to 
conduct this analysis in an even broader array of cohorts in the coming months. 
In conclusion, VACS Index 2.0 is highly predictive of risk of all-cause mortality among 
those on treatment for HIV infection. With use of continuous variables it is now better suited to 
application for individual patients. With addition of parameters readily obtained during routine 
clinical practice it is more discriminating than the original VACS Index. Its superior discrimination 
is robust across development and validation sets, among important clinical subgroups, and 
among individual cohorts. 
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Table 1. Characteristics of patients at a randomly selected visit date between 2000 and 2014, 
after a minimum of 1 year of antiretroviral therapy, in the development sample (VACS) and 
validation sample (ART-CC). 
    VACS   ART-CC 
  (N = 28390)  (N = 12109) 
Random visit date      
 
2000-2004 6587  (23)  1307  (11) 
2005-2009 7753  (27)  4744  (39) 
 2010-2014 14050  (49)  6058  (50) 
ART Initiation      
 1996-1998 7929  (28)  1696  (14) 
1999-2002 6454  (23)  3282  (27) 
 2003-2007 6510  (23)  3958  (33) 
 2008-2014 7497  (26)  3173  (26) 
Years on ART      
 Median (IQR) 4.2  (2.2-7.6)  4.2  (2.2-7.4) 
Age (years)      
 Median (IQR) 52  (46-59)  43  (36-49) 
Male 27696  (98)  8972  (74) 
Race      
 White 11576  (41)  6840  (56) 
 Black 13722  (48)  1403  (12) 
 Hispanic 2225  (8)  255  (2) 
 Other/unknown 867  (3)  3611  (30) 
CD4 cell count (cells/ul)     
 Median (IQR) 435  (249-643)  500  (335-690) 
HIV-1 RNA <= 500 copies/mL    
  21561  (76)  10650  (88) 
Hemoglobin (g/dl)      
 Median (IQR) 14.0  (12.8-15.1)  14.3  (13.0-15.3) 
FIB-4      
 <1.45 15782  (56)  8994  (74) 
 1.45-3.25 9722  (34)  2459  (20) 
 >3.25 2886  (10)  656  (5) 
eGFR (ml/min)      
 Median (IQR) 90  (73-105)  101  (87-113) 
Hepatitis C infection 5523  (19)  1803  (15) 
Albumin (g/dl)      
 Median (IQR) 4.0  (3.7-4.3)  4.3  (4.0-4.5) 
White blood count (k/ml)     
 Median (IQR) 5.5  (4.3-6.9)  5.8  (4.7-7.2) 
Body mass index,  kg/m2     
 Median (IQR) 25.3  (22.4-28.7)  24.2  (21.7-27.2) 
Low-risk* 6907  (24)   7303  (60) 
*Age <50 years, CD4 >= 200, and HIV-1 RNA <= 500 
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Figure 1. Discrimination of 5-year, all-cause mortality, for VACS Index 1.0 (left) and VACS 
Index 2.0 (right): a. VACS, ART-CC and individual ART-CC cohorts. LT50 = ART-CC, complete 
data available for less than 50% of eligible, GE50= ART-CC, complete data available for at least 
50% of eligible; b. VACS; c. ART-CC 
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Figure 2. Kaplan-Meier plots for all-cause mortality by decile of risk according to VACS Index 
1.0 and VACS Index 2.0, in development sample, VACS (a and b) and validation sample, ART-
CC (c and d). Further detail available in Appendix Table 4. 
  
Decile 1.0 2.0 1.0 2.0
100 1 98% 99% 92% 93%
2 95% 95% 82% 81%
80 3 93% 92% 75% 72%
4 90% 90% 63% 61%
60 5 86% 87% 58% 51%
6 82% 81% 45% 44%
40 7 81% 73% 40% 33%
8 68% 68% 28% 25%
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Figure 3. Discrimination of 5-year, all-cause mortality, for VACS Index 1.0 (left) and VACS 
Index 2.0 (right), in combined VACS and ART-CC data subgroups. Low-Risk = age <50 years, 
CD4 count > 200 cells/l, andHIV-RNA < 500 copies/mL. High-Risk = all others. 
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Figure 4. All-cause mortality rates during 5 years of follow-up by VACS Index 2.0 score. a. Low 
risk patients (age <50 years, CD4 >200 cells/ml, HIV-1 RNA <500 copies/mL), b. High risk 
patients (all others). 
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Appendix Table 1. VACS Index 2.0 Cox proportional hazards model, for 5-year, all-cause 
mortality, estimated in Veterans Aging Cohort Study, varying length of last value carried forward 
(LVCF).. 
 
 
*X1 = eGFR/10, X2 = (eGFR-35)/10, X3 = (eGFR-65)/10, X4 = (eGFR-115)/10. 
Main analysis LVCF 180 days Sensitivity LVCF 1 year
N 28390 28830
deaths 7293 7479
Parameter PE SE c2 p HR  (95% CI) PE SE c2 p HR  (95% CI)
Age (years), censored at 30-75, centered at (age-50)
X 0.056 0.012 22 <.0001 1.06  (1.03-1.08) 0.058 0.012 24 <.0001 1.06  (1.04-1.09)
X2 -0.004 0.004 2 0.22 1.00  (0.99-1.00) -0.006 0.004 3 0.11 0.99  (0.99-1.00)
X3 0.005 0.001 29 <.0001 1.01  (1.00-1.01) 0.005 0.001 30 <.0001 1.01  (1.00-1.01)
X -0.056 0.025 5 0.03 0.95  (0.90-0.99) -0.048 0.025 4 0.05 0.95  (0.91-1.00)
X2 -0.153 0.023 46 <.0001 0.86  (0.82-0.90) -0.149 0.023 43 <.0001 0.86  (0.82-0.90)
X3 0.024 0.002 94 <.0001 1.02  (1.02-1.03) 0.023 0.002 86 <.0001 1.02  (1.02-1.03)
X 0.513 0.033 247 <.0001 1.67  (1.57-1.78) 0.518 0.032 257 <.0001 1.68  (1.58-1.79)
X2 -0.422 0.041 109 <.0001 0.66  (0.61-0.71) -0.412 0.040 106 <.0001 0.66  (0.61-0.72)
X3 0.098 0.011 77 <.0001 1.10  (1.08-1.13) 0.095 0.011 73 <.0001 1.10  (1.08-1.12)
Hemoglobin (g/dl), censored at 9-16, centered at (14 - hemoglobin)
X -0.134 0.011 141 <.0001 0.88  (0.86-0.89) -0.132 0.011 142 <.0001 0.88  (0.86-0.90)
X2 0.026 0.006 16 <.0001 1.03  (1.01-1.04) 0.026 0.006 17 <.0001 1.03  (1.01-1.04)
X3 0.005 0.001 10 0.002 1.01  (1.00-1.01) 0.004 0.001 10 0.002 1.00  (1.00-1.01)
FIB-4, censored at .5 -7.5
X 0.220 0.028 62 <.0001 1.25  (1.18-1.32) 0.213 0.028 59 <.0001 1.24  (1.17-1.31)
X2 -0.009 0.003 7 0.008 0.99  (0.99-1.00) -0.008 0.003 7 0.0106 0.99  (0.99-1.00)
eGFR (ml/min), censored at 0-180,*
X1 -0.031 0.028 1 0.28 0.97  (0.92-1.03) -0.014 0.028 0 0.61 0.99  (0.93-1.04)
X2 -0.077 0.045 3 0.0917 0.93  (0.85-1.01) -0.107 0.045 6 0.0174 0.90  (0.82-0.98)
X3 0.106 0.027 16 <.0001 1.11  (1.06-1.17) 0.131 0.026 25 <.0001 1.14  (1.08-1.20)
X4 0.133 0.034 15 0.0001 1.14  (1.07-1.22) 0.093 0.033 8 0.0054 1.10  (1.03-1.17)
Hepatitis C co-infection
Yes 0.342 0.028 147 <.0001 1.41  (1.33-1.49) 0.350 0.028 160 <.0001 1.42  (1.35-1.50)
Albumin (g/dl), censored at 2-5, centered at (albumin - 4)
X -0.443 0.034 165 <.0001 0.64  (0.60-0.69) -0.467 0.034 189 <.0001 0.63  (0.59-0.67)
X2 0.104 0.051 4 0.04 1.11  (1.00-1.23) 0.141 0.050 8 0.01 1.15  (1.04-1.27)
X3 0.028 0.027 1 0.30 1.03  (0.98-1.08) 0.055 0.026 4 0.04 1.06  (1.00-1.11)
X 0.126 0.011 130 <.0001 1.13  (1.11-1.16) 0.125 0.011 132 <.0001 1.13  (1.11-1.16)
X2 0.020 0.004 30 <.0001 1.02  (1.01-1.03) 0.021 0.004 35 <.0001 1.02  (1.01-1.03)
X3 -0.004 0.001 23 <.0001 1.00  (0.99-1.00) -0.005 0.001 27 <.0001 1.00  (0.99-1.00)
X -0.055 0.003 388 <.0001 0.95  (0.94-0.95) -0.055 0.003 407 <.0001 0.95  (0.94-0.95)
X2 0.004 0.000 62 <.0001 1.00  (1.00-1.01) 0.004 0.000 62 <.0001 1.00  (1.00-1.00)
White blood count (k/ml), censored at 2.5-11, centered at (WBC - 5.5)
Body mass index, kg/m2, censored at 15-35, centered at (BMI - 25)
HIV-1 RNA (log copies/ml), censored at 1.3- 5.0, centered at (logVL - 2)
CD4 cell count (cells/ml), censored at 0-1000, as ln (1000-CD4)
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Appendix Table 2. Range of plausible values and associated VACS Index 2.0 score, setting all 
other predictors to their median value. 
Predictor Median  Range of plausible values* 
Age (years)     
Value 52  30 35 40 45 50 55 60 65 70 75 
Score **   32 38 41 43 44 45 47 49 53 59 
CD4 cell count (cells/ml)           
Value 435  10 100 200 300 400 500 600 700 800 900 
Score **   55 53 51 48 45 43 40 37 34 32 
HIV-1 RNA (log copies/mL)          
Value 1.7  1.3 1.5 1.8 2.0 2.5 3.0 3.5 4.0 4.5 5 
Score **   37 41 46 48 51 52 51 50 51 55 
Hemoglobin (g/dl)     
Value 14  9 9.5 10 10.5 11 12 13 14 15 16 
Score **   58 58 57 55 54 51 47 44 42 42 
FIB-4     
Value 1.34  0.50 1.00 1.45 2.00 3.25 4.00 5.00 6.00 7.00 7.50 
Score **   41 43 45 47 51 53 56 58 60 61 
eGFR (ml/min)     
Value 90  0 20 40 60 80 100 120 140 160 180 
Score **   53 51 49 45 44 44 46 51 55 60 
Hepatitis C co-infection     
Value No  Yes          
Score **   51                   
Albumin (g/dl)     
Value 4  2.00 2.25 2.50 2.75 3.00 3.25 3.5 4.00 4.50 5.00 
Score **   65 62 59 57 54 52 49 44 41 39 
White blood count (k/ml     
Value 5.5  2.5 3 4 5 6 7 8 9 10 11 
Score **   43 42 42 43 46 49 51 54 55 55 
Body mass index ( kg/m2)     
Value 25.3  15 17 18 20 22 24 26 28 30 35 
Score **   62 57 55 51 48 46 44 42 41 41 
* Clinically meaningful values between lowest and highest values used in development model. 
**Score = 44 when all values are set to their median and Hepatitis C is set to no. 
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Appendix Table 3. Number at risk, number of deaths, distribution of VACS Index 2.0 scores, 
and all-cause mortality hazard ratio (HR) per 5 points, in the development sample (VACS) and 
validation sample (ART-CC), overall and by individual cohort (A-I). 
        VACS Index 2.0 Score   
Risk of all-cause 
mortality, per 5 points 
 N Deaths  Median 25th 75th 1st 99th  HR (95% CI) 
VACS 
          
28,390  
             
7,293   51 39 66 15 111  1.31  (1.30-1.31) 
ART-CC 
        
12,109  
                
722   41 33 52 14 97  1.37  (1.35-1.39) 
A 
             
1,011  
                   
40   41 31 52 14 91  1.41  (1.32-1.52) 
B 
                
944  
                   
95   42 34 53 17 98  1.38  (1.31-1.44) 
C 
             
1,872  
                
112   35 27 46 11 93  1.37  (1.32-1.42) 
D 
             
1,509  
                   
78   44 36 54 18 89  1.38  (1.31-1.45) 
E 
                
863  
                   
73   42 33 54 15 104  1.34  (1.28-1.41) 
F 
             
1,899  
                
111   42 34 53 17 102  1.38  (1.33-1.43) 
G 
             
2,231  
                
120   42 34 54 16 94  1.40  (1.34-1.46) 
H 
                
891  
                   
53   44 34 54 19 103  1.34  (1.27-1.42) 
I 
                
889  
                   
40    41 33 50 17 95   1.40  (1.30-1.51) 
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Appendix Table 4. Number at risk, number of deaths, distribution of VACS Index 2.0 scores, 
and all-cause mortality hazard ratio (HR) per 5 points, in the development sample (VACS) and 
validation sample (ART-CC), overall and by individual cohort (A-I).  
 
 
N Died Survival Left Died Survival Left Died Survival Left Died Survival Left
VACS sample
Overall 28390 348 1706 2833 7293
Decile
1 10646 12 100% 10634 113 99% 10533 199 98% 10447 732 92% 5247
2 4763 17 100% 4745 109 98% 4653 220 95% 4543 737 82% 2325
3 3249 21 99% 3228 122 96% 3127 225 93% 3023 723 75% 1469
4 2239 27 99% 2211 141 94% 2097 233 90% 2005 737 63% 898
5 1864 28 98% 1835 140 92% 1722 260 86% 1603 718 58% 700
6 1449 29 98% 1419 157 89% 1291 264 82% 1185 729 45% 427
7 1268 30 98% 1237 148 88% 1119 242 81% 1026 716 40% 353
8 1083 45 95% 1033 215 80% 867 351 68% 731 743 28% 204
9 962 41 96% 920 226 76% 733 370 62% 592 728 21% 137
10 867 98 88% 763 335 61% 531 469 46% 398 730 13% 64
1 12381 10 100% 12371 100 99% 12281 185 99% 12196 729 93% 5586
2 4275 16 100% 4259 96 98% 4179 196 95% 4079 729 81% 2324
3 2853 24 99% 2827 105 96% 2747 220 92% 2633 730 72% 1405
4 2029 14 99% 2014 108 95% 1919 207 90% 1821 730 61% 878
5 1597 23 99% 1573 116 93% 1480 213 87% 1383 729 51% 593
6 1391 19 99% 1371 140 90% 1249 260 81% 1130 729 44% 437
7 1149 19 98% 1128 175 85% 974 305 73% 844 729 33% 279
8 1016 35 96% 979 203 80% 812 324 68% 691 729 25% 183
9 888 61 93% 827 264 70% 623 397 55% 491 729 15% 95
10 811 127 84% 678 399 51% 411 526 35% 285 730 8% 41
Overall 12109 47 192 318 722
Decile
1 4824 2 100% 4789 10 100% 4443 23 99% 3915 72 97% 1398
2 2087 1 100% 2065 8 100% 1928 19 99% 1745 64 95% 694
3 1824 5 100% 1800 16 99% 1688 31 98% 1539 82 94% 610
4 1148 1 100% 1138 10 99% 1057 20 98% 960 68 91% 394
5 824 2 100% 816 20 97% 739 31 96% 670 75 87% 258
6 492 4 99% 485 21 95% 428 35 92% 376 72 81% 149
7 362 7 98% 350 24 93% 300 36 89% 254 73 71% 82
8 206 4 98% 202 21 89% 169 32 83% 141 71 53% 39
9 196 9 95% 186 26 86% 153 46 74% 120 72 52% 43
10 146 12 91% 130 36 74% 97 45 67% 78 73 35% 19
1 5838 1 100% 5785 10 100% 5356 27 99% 4662 73 98% 1559
2 2397 1 100% 2379 10 100% 2224 16 99% 2051 72 95% 865
3 1247 3 100% 1240 14 99% 1169 26 98% 1070 72 92% 489
4 884 1 100% 876 12 99% 812 24 97% 755 71 89% 335
5 618 4 99% 609 12 98% 557 29 95% 501 73 83% 197
6 359 1 100% 355 19 94% 305 28 91% 267 73 69% 83
7 311 3 99% 302 22 92% 255 38 86% 213 72 69% 84
8 190 6 97% 182 20 89% 159 33 81% 133 72 52% 46
9 151 11 92% 139 29 80% 109 44 69% 88 71 37% 15
10 114 16 85% 95 44 59% 61 53 51% 47 73 25% 15
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Appendix Figure 1. Model development in VACS Cohort comparing model fit using Akaike’s 
information criterion (AIC) and discrimination using Harrell’s c-statistic 
